Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 5 of 27
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02057133
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
NCT01594723
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain
NCT07641504
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
NCT07641517
A Study of LY3971297 in Participants With Heart Failure
NCT07547540
A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants
NCT07662798
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
NCT07654972
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
NCT07612267
A Study of [14C]-LY4064809 in Healthy Participants
NCT07519525
A Study of LY3549492 in Healthy Weight Adult Participants
NCT07085468
A Study of Remternetug (LY3372993) in Healthy Participants
NCT07056309
A Study of [14C]-LY4065967 in Healthy Participants
NCT07039045
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
NCT07030868
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
NCT06916065
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
NCT06890611
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
NCT06824051
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
NCT06719128
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
NCT06704763
A Study of [14C]-LY3866288 in Healthy Participants
NCT06644378
A Study of LY3866288 in Healthy Participants
NCT06641037
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
NCT06584916
A Study of LY3532226 in Participants With Obesity
NCT06557356
A Study of Subcutaneous Injection in Healthy Participants
NCT06516913
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
NCT06440980
A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
NCT06475729
A First-In-Human Study of LY3985297 in Healthy Participants
NCT06395012
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
NCT06444165
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
NCT06370728
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660
A Study of LY3841136 in Overweight and Obese Participants
NCT06345066
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
NCT06313528
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06230523
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
NCT05999968
A Relative Bioavailability Study of LY3454738 in Healthy Participants
NCT06173895
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
NCT06192108
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
NCT06186622
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06176768
A First-In-Human Study of LY3839840 in Healthy Participants
NCT06153355
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06124807
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
NCT06132126
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
NCT06109311
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
NCT06119529
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
NCT06111521
A Study of [14C]-LOXO-783 in Healthy Adult Participants
NCT06102512
A Phase I Study of LY3502970 in Healthy Participants
NCT06085482
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
NCT06074562
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
NCT06045221
A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants
NCT06052462
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.